Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

of CVD for people aged 18 to 40 with type 1 diabetes, including those who have had diabetes for 10 years or less. [May 2023, amended December 2023] 1.6.12 When starting treatment with a statin for adults with type 1 diabetes, use atorvastatin 20 mg. [May 2023] For a short explanation of why the committee made these recommendations and how they might affect practice, see the rationale and impact section on lipid-lowering treatment for primary prevention of CVD. Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects. Optimising statin treatment See the section on optimising statin treatment. Assessing response to treatment See the section on assessing response to treatment. Escalating treatment for people on statins 1.6.13 Ezetimibe, co-administered with a statin, is recommended as an option in NICE technology appraisal guidance for treating primary hypercholesterolaemia in some adults who have started statin therapy when serum total or low-density lipoprotein (LDL) cholesterol concentration is not appropriately controlled. For full details, see the guidance on ezetimibe (TA385, 2016). 1.7 Lipid-lowering treatment for secondary prevention of cardiovascular disease These recommendations apply to people with and without type 1 and 2 diabetes. Also see
